Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20165 | 0.82 | DHFR (0.33) | PNP | |
| SCHEMBL1665906 | 0.82 | PNP (0.31) | PNP | |
| SCHEMBL2512344 | 0.80 | SUMO1 (0.36) | PNP | |
| SCHEMBL26506 | 0.80 | SUMO1 (0.36) | PNP | |
| SCHEMBL21877314 | 0.79 | PNP (0.31) | PNP | |
| SCHEMBL29512549 | 0.78 | SUMO1 (0.36) | PNP | |
| SCHEMBL20744797 | 0.77 | — | — | |
| SCHEMBL356920 | 0.77 | BACE1 (0.39) | PNP | |
| SCHEMBL542389 | 0.77 | PNP (0.37) | PNP | |
| SCHEMBL18132313 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240360472-A1 | POLYNUCLEOTIDES AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4381080-A1 | POLYNUCLEOTIDES AND USES THEREOF | Strand Therapeutics Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| WO-2000069876-A1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069877-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PNP 42/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PNP 77/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PNP 77/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PNP 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.